Cytokine signaling and Epstein-Barr virus-mediated cell transformation

Cytokine and Growth Factor Reviews

Volumn 12, Issue 2-3, 2001, Pages 259-270

  Mosialos, George ^a  

^a BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; EBV ASSOCIATED MEMBRANE ANTIGEN; EBV-ASSOCIATED MEMBRANE ANTIGEN; GROWTH FACTOR; LATENT MEMBRANE PROTEIN 1; MATRIX PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS PROTEIN;

ANIMAL; AUTOCRINE EFFECT; B LYMPHOCYTE; BIOLOGICAL MODEL; CELL GROWTH; CELL TRANSFORMATION; EPSTEIN BARR VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PARACRINE SIGNALING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VIRUS INFECTION;

ANIMALS; B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; HERPESVIRUS 4, HUMAN; HUMANS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 0034948735     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(00)00035-6     Document Type: Review

References (117)

1. Epstein-Barr virus
2. Is EBV persistence in vivo a model for B cell homeostasis?
3. EBV persistence in memory B cells in vivo
4. Epstein-Barr virus and its replication
5. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein
6. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa
7. Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless
8. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles
9. Regulation of T cell fate by Notch
10. Functional replacement of the intracellular region of the Notch 1 receptor by Epstein-Barr virus nuclear antigen 2
11. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence -specific DNA-binding protein J kappa
12. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa)
13. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation
14. Epstein-Barr vires leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: A role for the W1W2 repeat domain
15. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
16. Epstein-barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt
17. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase /Akt pathway
18. Epstein-barr virus transformation: Involvement of latent membrane protein 1-mediated activation of NF-kappaB
19. Interleukin-10
20. The nucleotide sequence of a messenger RNA transcribed in latent growth transforming virus infection indicates that it may encode a membrane protein
21. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells
22. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: Deletion of the amino terminus abolishes activity
23. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B-lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23
24. Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: Cell-type-independent induction of CD23, CD21, and ICAM- 1
25. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain
26. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor
27. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death
28. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B
29. Expression of the Epstein-Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines
30. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line
31. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene
32. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis
33. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation
34. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus
35. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6
36. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells
37. Transformation of Balb/3T3 cells by the BNLF-1 gene of Epstein-Barr virus
38. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice
39. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B-lymphocyte responses
40. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation
41. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma
42. The origin of Hodgkin and Reed/ Sternberg cells in Hodgkin's disease
43. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis
44. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus
45. An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes
46. Posttranslational processing of the Epstein-Barr virus-encoded p63/LMP protein
47. Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association
48. Epstein-Barr virus latent membrane protein: Induction of B-cell activation antigens and membrane patch formation does not require vimentin
49. The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts
50. The multiple membrane-spanning segments of the BNLF-1 oncogene from Epstein-Barr virus are required for transformation
51. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP1 are required for transformation of rat-1 fibroblasts
52. High concentration of the EBV latent membrane protein 1 in glycosphingolipid-rich complexes from both epithelial and lymphoid cells
53. Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling
54. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues
55. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B-lymphocyte growth transformation
56. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B-lymphocyte growth transformation and activate NF-kappaB
57. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation
58. Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus
59. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade
60. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein- Barr virus-encoded latent membrane protein 1 (LMP1)
61. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase
62. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression
63. Relationship between IkappaBalpha constitutive expression, TNFalpha synthesis, and apoptosis in EBV-infected lymphoblastoid cells
64. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells
65. Inducible loss of NF-kappaB activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B-lymphocytes
66. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2
67. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production
68. Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphhocyte growth transformation
69. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
70. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation
71. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)
72. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development
73. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family
74. Tumor necrosis factor receptor-associated factors (TRAFs) - A family of adapter proteins that regulates life and death
75. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-kappaB activation
76. Localization of the major NF-kappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs
77. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3
78. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein
79. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex
80. Assembly and regulation of the CD40 receptor complex in human B cells
81. Lymphotoxin-β receptor signaling complex: The role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor κB
82. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation
83. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule
84. The CD40 antigen and its ligand
85. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival
86. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor
87. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation
88. Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions
89. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1
90. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity
91. MAP3K -related kinase involved in NF-κB induction by TNF, CD95 and IL-1
92. Signaling by proinflammatory cytokines: Oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain
93. MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration
94. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase
95. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta
96. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain
97. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice
98. Activation of stress-activated protein kinase/ c-Jun N-terminal kinase, but not NF-kappaB, by the tumor necrosis factor (TNF) receptor 1 through a TNF receptor-associated factor 2- and germinal center kinase related-dependent pathway
99. ASK1 is essential for JNK/SAPK activation by TRAF2
100. Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogen- activated protein kinase kinase kinase upstream of MKK6 and p38
101. Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation
102. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1
103. Epstein-Barr virus transformation induces B-lymphocytes to produce human interleukin 10
104. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B-lymphocytes
105. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines
106. Regulation of B-cell growth and imumnoglobulin gene transcription by interleukin-6
107. Expression of an exogenous interleukin 6 gene in human Epstein-Barr virus B cells confers growth advantage and in vivo tumorigenicity
108. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis
109. Autocrine models of B-lymphocyte growth. II. Interleukin-1 supports the proliferation of transformed lymphoblasts but not the stimulation of resting B cells triggered through their receptors for antigen
110. Interleukin-5 is an autocrine growth factor for Epstein-Barr virus-transformed B-lymphocytes
111. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines
112. TGF-beta signal transduction
113. Loss of transforming growth factor beta 1 receptors and its effects on the growth of EBV-transformed human B cells
114. Resistance to TGF-betal correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B-lymphoblastoid cell lines
115. Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells
116. Synergistic regulation of the human interleukin-12 p40 promoter by NFkappaB and Ets transcription factors in Epstein-Barr virus-transformed B cells and macrophages
117. Interleukin-12 expression in B cells by transformation with Epstein-Barr virus